New billboards in the Mount Rushmore state reflect MISSD’s bold “50 in 5” initiative. 50 States, 5 Years, 1 Mission: Raise Akathisia Awareness to Save Lives.

“Just as South Dakota’s Badlands conceal sudden drop-offs—and Mount Rushmore reminds us of enduring legacies—akathisia can surface without warning, causing avoidable suffering and tragedies. But with greater awareness and education, we can build a legacy of prevention, early diagnosis, and better care,” said Wendy Dolin, founder of MISSD.

Read more at https://www.einpresswire.com/article/829561721/missd-launches-national-campaign-to-prevent-medication-induced-harm.

Outro Health has just released an excellent webinar about SSRI tapering. Most healthcare professionals remain unaware of the slow process of safe tapering, and that for some people, getting off depression pills is a worse experience than what they experienced before initially being prescribed the drugs. Outro Health is an evidence-based tapering service for people looking to stop their antidepressants. Listen and learn at https://www.youtube.com/watch?v=jSEEAfbuCv8.

Does pharma sprinkle “commercially sensitive information” into drug protocol docs to later block public access to efficacy and safety data? Or is their “commercially sensitive” claim pure fiction?

This recent blog posts shows how pharma gets drug regulators to cover for them when it comes to freedom of information requests–requests that can benefit the public and improve personal decision making regarding healthcare choices. “Common sense suggests drug company commercial interests should never over-ride patient welfare.” Read more at https://davidhealy.org/secret-moderna-trial-documents/.